StockData

Nuvation Bio vs Verastem

NUVB and VSTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NUVB and VSTM compare

Nuvation Bio is the larger company, worth 1.9 times as much as Verastem ($1.3B against $697M).

Nuvation Bio keeps more of each dollar of sales as profit, with a net margin of −88.2% compared with −232% at Verastem.

Nuvation Bio scores higher on the StockData Score (4 against 3 for Verastem), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNUVBVSTM
Size and price
Market cap$1.3B$697M
Share price$3.84$7.70
Change, 1 year−18.1%−5.1%
Change, 5 years−53.0%−76.1%
Beta (5Y)1.792.60
Employees298102
StockData Score
Total score4 (better)3
Valuation score00
Growth score11
Performance score11
Health score2 (better)1
Dividend score00
Valuation
P/S7.9× (better)8.0×
P/B5.3× (better)14.0×
Fair value$1.94–
Margin of safety−97.7%–
Growth
Revenue growth (TTM)1084%–
Revenue growth, 5Y average–−19.0%
Profitability
Operating margin−81.0% (better)−183%
Net margin−88.2% (better)−232%
Return on equity−47.8% (better)−471%
Financial health
Debt / equity0.02–
Interest coverage−5.4× (better)−108.3×
Current ratio8.37 (better)2.25
Altman Z-score0.09 (better)−7.27
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions66.5%109%
Held by insiders24.6%1.8%
Insider net buying, 12 months−$4.5M−$816K (better)
Superinvestors holding2–
Short interest, % of float23.4%22.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.